Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Inclusion criteria

• ✓. LVEF ≥45% by MUGA or rest ECHO
• ✓. Diffusion capacity \>45% (adjusted for hemoglobin) as predicted by pulmonary function testing
• ✓. Platelet count ≥ 20 x 109/L
• ✓. ALT and AST ≤ 2.5 x ULN
• ✓. Total bilirubin ≤ 2.5 x ULN; except if the elevation is due to Gilbert's syndrome
• ✓. Calculated creatinine clearance \> 40 mL/min
• ✓. Have a negative serum pregnancy test (β-human chorionic gonadotropin \[β-hCG\]) within 14 days prior to enrollment (and pre-AHCT per institutional guidelines)
• ✓. For 180 days after receiving plinabulin practice a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: e.g., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization (the vasectomized partner should be the sole partner for that subject); true abstinence (when this is in line with the preferred and usual lifestyle of the subject)